EU approves Sanofi and Regeneron’s dupilumab in eczema

Share this post

PARIS (Reuters) – The European Commission approved Regeneron Pharmaceuticals’ and Sanofi’s key biologic treatment dupilumab for moderate-to-severe atopic dermatitis, the two companies said on Thursday.

This post was syndicated from Reuters: Health News. Click here to read the full text on the original website.


Share this post

Be the first to comment

Leave a Reply